22.418 articles found

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.

de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ.

Brain · 2004-08-25

DOI: 10.1093/brain/awh290PMID: 15329355

Gene therapy in Parkinson's disease.

Eberhardt O, Schulz JB.

Cell Tissue Res · 2004-08-19

DOI: 10.1007/s00441-004-0947-xPMID: 15322915

1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders

SPINKS DANIEL, ARMER RICHARD E, MILLER DAVID J, RANKOVIC ZORAN, SPINKS GAYLE, MESTRES JORDI, JAAP DAVID R.

· 2004-08-12

Stem cell therapy for Parkinson's disease: where do we stand?

Roybon L, Christophersen NS, Brundin P, Li JY.

Cell Tissue Res · 2004-08-11

DOI: 10.1007/s00441-004-0946-yPMID: 15309619

Prevention and treatment of synucleinopathic and amyloidogenic disease

SCHENK DALE B, MASLIAH ELIEZER.

· 2004-08-09

METHOD FOR ESTIMATING DEVELOPING POSSIBILITY OF PARKINSON'S DISEASE, METHOD FOR GENETIC DIAGNOSIS OF PARKINSON'S DISEASE AND METHOD FOR TREATMENT OF PARKINSON'S DISEASE

SORA ICHIRO, KOBAYASHI HIDEAKI.

· 2004-08-03

NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.

Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD.

Neuropharmacology · 2004-08-01

DOI: 10.1016/j.neuropharm.2004.03.011PMID: 15223297

Dementia in Parkinson's disease: cause and treatment.

Emre M.

Curr Opin Neurol · 2004-08-01

DOI: 10.1097/01.wco.0000137529.30750.abPMID: 15247534

Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.

Townsend M, MacIver DH.

Heart · 2004-08-01

DOI: 10.1136/hrt.2004.036236PMID: 15253989

Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease.

Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, Barbosa ER, Valente KD, Pascual-Leone A, Marcolin MA.

J Neurol Neurosurg Psychiatry · 2004-08-01

DOI: 10.1136/jnnp.2003.027060PMID: 15258224

Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease.

Clarke CE.

Lancet Neurol · 2004-08-01

DOI: 10.1016/s1474-4422(04)00823-3PMID: 15261607

Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.

Thanvi BR, Lo TC.

Postgrad Med J · 2004-08-01

DOI: 10.1136/pgmj.2003.013912PMID: 15299154